Inclusion Criteria:

          -  12 years of age or older (*Restrictions apply. Not all therapies are available for
             patients <18)

          -  Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or
             B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer
             treatment or for whom, in the opinion of the treating physician, no such treatment is
             available or indicated

          -  Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)

          -  Patients must have acceptable organ function as defined below. However, as noted
             above, drug-specific inclusion/exclusion criteria specified in the protocol appendix
             for each agent will take precedence for this and all inclusion criteria:

               1. Absolute neutrophil count ≥ 1.5 x 106/µl

               2. Hemoglobin > 9.0 g/dl

               3. Platelets > 75,000/µl

               4. Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome

               5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)
                  and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) <
                  2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with
                  known hepatic metastases)

               6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50
                  mL/min/1.73 m2

          -  Patients must have disease that can be objectively measured by physicial or
             radiographic exam or evaluable disease (per RECIST v1.1 for solid tumor, Lugano
             criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for
             multiple myeloma), defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded for non-nodal lesions and
             short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with
             spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a
             subcutaneous or superficial lesion that can be measured with calipers by clinical
             exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable
             disease by physical or radiographic examination but do not meet these definitions of
             measurable disease are eligible and will be considered to have evaluable disease.
             Patient's whose disease cannot be objectively measured by physical or radiographic
             examination (e.g., elevated serum tumor marker only, bone-only disease without an
             identifiable soft tissue component, or patients with only assessable non-measurable
             disease) are NOT eligible.

          -  Results must be available from a genomic test or immunohistochemistry (IHC) test for
             protein expression performed in a Clinical Laboratory Improvement Amendments
             (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York
             State accredited (for labs offering services to residents of NY) laboratory. Labs that
             have registered the test with the NIH Genetic Testing Registry or that provide a
             report that has been designated as optimized for TAPUR participation are preferred,
             but not required. The genomic or IHC test used to qualify a patient for participation
             in TAPUR may have been performed on any specimen of the patient's tumor obtained at
             any point during the patient's care at the discretion of the patient's treating
             physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies")
             will also be acceptable if the genomic analysis is performed in a laboratory that
             meets the criteria described above.

          -  Ability to understand and the willingness to sign a written informed consent/assent
             document.

          -  Have a tumor genomic profile for which single agent treatment with one of the FDA
             approved targeted anti-cancer drugs included in this study has potential clinical
             benefit based on the criteria described in protocol.

          -  For orally administered drugs, the patient must be able to swallow and tolerate oral
             medication and must have no known malabsorption syndrome.

          -  Because of the risks of drug treatment to the developing fetus, women of child-bearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) for the duration of study participation, and for four
             months following completion of study therapy. Should a woman become pregnant or
             suspect she is pregnant while participating in this study or if she is the partner of
             a male participant in this study and becomes pregnant while he is participating in
             this study, she should inform her or her partner's treating physician immediately as
             well as her obstetrician. Female study patients who become pregnant must immediately
             discontinue treatment with any study therapy. Male patients should avoid impregnating
             a female partner. Male study patients, even if surgically sterilized, (i.e.
             post-vasectomy) must agree to one of the following: practice effective barrier
             contraception during the entire study treatment period and for a specified amount of
             time the last dose of study drug, or completely abstain from sexual intercourse.

        Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have
        measurable and evaluable disease per RECIST v1.1.

        Exclusion Criteria:

          -  Patients whose disease is not measurable or cannot be assessed by radiographic imaging
             or physical examination (e.g., elevated serum tumor marker only) are not eligible

          -  Patients with primary brain tumors or leptomeningeal metastases are excluded.

          -  Patients with previously treated brain metastases are eligible, provided that the
             patient has not experienced a seizure or had a clinically significant change in
             neurological status within the 3 months prior to registration. All patients with
             previously treated brain metastases must be clinically stable for at least 1 month
             after completion of treatment and off steroid treatment for one month prior to study
             enrollment.

          -  Patients with known progressive brain metastases are eligible but additional
             eligibility criteria apply.

        Note: there are additional exclusion criteria that may apply